NCT03147742 is a clinical trial of Ruxolitinib in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation.

Who is sponsoring NCT03147742?

NCT03147742 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03147742?

Interventions in NCT03147742: Ruxolitinib.

What condition does NCT03147742 study?

NCT03147742 studies Graft-versus-host Disease (GVHD).

Is NCT03147742 still recruiting?

NCT03147742 is currently approved for marketing. Last updated 7 June 2022.

Last reviewed 2022-06-07 · How we verify

NCT03147742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

APPROVED FOR MARKETING Last updated 7 June 2022

What this trial tests

trial testing Ruxolitinib in Graft-versus-host Disease (GVHD). Approved for marketing.

Quick facts

Lead sponsor	Incyte Corporation
Status	APPROVED FOR MARKETING
Study type	EXPANDED_ACCESS
Sites	33 locations across United States

Drugs / interventions tested

Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Graft-versus-host Disease (GVHD) — all drugs for Graft-versus-host Disease (GVHD) →

Sponsor

Incyte Corporation — full company profile →

Who can join

12 and older, any sex, with Graft-versus-host Disease (GVHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

A Comprehensive Overview of Globally Approved JAK Inhibitors.
Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, et al · · 2022 · cited 222× · PMID 35631587 · DOI 10.3390/pharmaceutics14051001
Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F, Meier K, Ghoreschi K. · · 2019 · cited 199× · PMID 31849996 · DOI 10.3389/fimmu.2019.02847
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA, Choi J, Staser K, DiPersio JF. · · 2018 · cited 82× · PMID 29289756 · DOI 10.1016/j.bbmt.2017.12.797
New and emerging therapies for acute and chronic graft <i>versus</i> host disease.
Hill L, Alousi A, Kebriaei P, Mehta R, et al · · 2018 · cited 81× · PMID 29317998 · DOI 10.1177/2040620717741860
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Jain NK, Tailang M, Jain HK, Chandrasekaran B, et al · · 2023 · cited 24× · PMID 37021053 · DOI 10.3389/fphar.2023.1135145

Verify or expand the search:

Other trials of Ruxolitinib

Trials testing the same drug.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting

Other recruiting trials for Graft-versus-host Disease (GVHD)

Currently open trials in the same condition.

NCT06626737 — Dapagliflozin in Allo-HCT for aGVHD · Phase 2 · recruiting
NCT06615050 — A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil · Phase 3 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03147742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 7 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03147742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing